

**Next Lecture after Christian Cachard:**

# • PART 2

**The Second part will be devoted to hybrid devices, what complementarities are obvious. What they actually bring as decisive progresses at hospital, what are the main trends in evolution ....**

**Lecture 2.**

- **6 Image fusion / Hybrids**

# Imaging modalities today



Hardware combination Evolution / Revolution

Imaging Modality	Spatial Resolution (mm)	Acquisition time per frame(s)	Molecular probe mass required (ng)	Molecular sensitivity (mol/L)	Tissue penetration depth (mm)	Signal quantification capabilities
<b>PET</b>	1-2 (animal) <u>6-10 (clinical)</u>	1-300	<u>1-100</u>	<u>10<sup>-11</sup>-10<sup>-12</sup></u>	>300	<u>High</u>
SPECT	0.5-2 (animal) <u>7-15 (clinical)</u>	60-2000	<u>1-100</u>	10 <sup>-10</sup> -10 <sup>-11</sup>	>300	Medium-High
Optical	2-5 (visible to IR)	10-2000	10 <sup>3</sup> -10 <sup>6</sup>	10 <sup>-9</sup> -10 <sup>-11</sup>	1-20	Low
MRI	0.025-0.1 (animal) <u>0.2 (clinical)</u>	0.1-100	10 <sup>3</sup> -10 <sup>6</sup>	<u>10<sup>-3</sup>-10<sup>-5</sup></u>	>300	High
US	0.05-0.5 (animal) 0.1-1 (clinical)	0.1-100	10 <sup>3</sup> -10 <sup>6</sup>	Not well characterized	1-300	Low
<b>CT</b>	0.03-0.4 (animal) <u>0.5-1 (clinical)</u>	1-300	NA	Not well characterized	>300	Medium-High

From Craig S Levin. Eur J Nucl Med & Mol Imag. 2005, 32(14), S-325-45

# EVOLUTION in MEDICAL IMAGING (combination of existing equipment)


Example:

**CT**




**PET**

movement




Data from Different Systems:  
need software to register and fuse images (I)



Data taken at different time / in different configuration / in different places...

Fusion only by software

Images from Hybrid Systems:  
Sequential Acquisitions




Data taken at sequential time / with minimal movement of patient

Fusion by software


(from D. Townsend 2014)

**1990**




Software-based fusion (semi-automated)

**1993 - 1998**



Hardware-adjunction: Prototype designs

**2001**



Hardware-adjunction: Commercial PET/CT

**2004**




Hardware-adjunction: Commercial SPECT/CT

**2010**





Hardware-based fusion: Commercial PET/MR





Bruce H Hasegawa, PhD, 1951-2008  
Participant ESI, Archamps In 1997

# SPECT/CT in the clinic

(From D. Townsend 2014)




Conventional SPECT



SIEMENS xSPECT



Symbia TX



Discovery NM/CT 670

**“CT is potentially more valuable for SPECT than for PET”**


*Bailey DL. Eur J Nuc Med & Mol Imag 2003; 30(7):1045-1046*

# REVOLUTION in MEDICAL IMAGING

(Integrated devices from technical developments)

Integrated better than separated !

Example: **MRT**





**PET**

No movement !




(same hardware)



**REVOLUTION is simultaneous Acquisitions without patient displacement !!**

# *Integrated device versus Sequential one PET-MR*



## Integrated

Short acquisition time ←  
More accurate fusion ←  
Dynamic data simultaneously  
MR-based motion correction.

Technically complex  
Higher cost ←

## Sequential

Technically easy ←  
Less expensive ←

No simultaneous imaging ←  
Longer acquisition time ←  
Less accurate fusion  
Needs more space




# History




## PET/MRI Then and Now

**1996**  
**Laboratory**  
**development**



Shao Y, Cherry SR, Farahani K et al. *Phys Med Biol* 42: 1965-70 (1997)

**2011**  
**Tests in**  
**Hospital**  
**(MGH Boston)**



Courtesy of Henrik Michaely and Alex Guimaraes, MGH

# Two Complementary devices







## Why PET/MRI

### MRI

- high resolution
- high soft tissue contrast ( $\neq$  CT)
- No radiation exposure ( $\neq$  CT)
- Functional capabilities (BOLD, MRS)

### PET

- high sensitivity
- target specific tracer
- molecular imaging with picomolar sensitivity



$$1 + 1 = >3?$$


# Challenges for PET/MR



- MR-compatible PET detectors from technics (APD, Si-PM..) OK
- PET attenuation correction factors from MR images ??
- role for simultaneous MR and PET acquisition? OK
- financial cost (eventually) of the PET/MR system ??
- Used routinely for Small Animal PET then for patient OK

But already  
exceptionnal images ...

## MR-PET Design for Whole Body Applications



# Why Imaging (SPECT, PET..)



is useful in Oncology in:

- Help in **Diagnosis**
- Help in **Treatment plannings**
- Help **Post-treatment survey**

**SPECT-CT & PET-CT are better than SPECT & PET alone....**


\*



**28 min** (8/05)


**10.6 mCi, 115 min pi**  
**4 min/bed, 7 beds**  
**3i / 8s; 6f**

Two imagings  
at a 9 months  
interval :



**15 min 9 months later** (5/06)

**10.5 mCi, 104 min pi**  
**3 min/bed, 5 beds**  
**3i / 8s; 6f**



**Scan duration: 15 min**

*Biograph*

48 year-old female (200 lbs) with history of breast cancer. First PET showed intense uptake in bilateral supraclavicular, mediastinal and right parasternal nodes and the thyroid. 9 months later PET showed significant disease progression including sternum and pelvic region

**Restaging gastric cancer**



**Pre-therapy** (400)




**With Biograph Post-therapy** (1000)


**6 months later**

Scan duration: 15 min  
5 beds; 3 min/bed; 8s/3i/6F  
10.6 mCi; 90 min post-injection

Scan duration: 15 min  
5 beds; 3 min/bed; 8s/3i/6F  
9.8 mCi; 90 min post-injection



**Pre-therapy**



**Post-therapy**

A 52 year-old male patient with history of gastric cancer imaged pre- and post-therapy (after 1/2 year)


# TREATMENT PLANNINGS

(Will be explained later by Alex Rijnders for Brachytherapy)



Treatment plannings  
are compulsory for  
correct treatment

## The Software start from Images



- external contours
- densities
- anatomical structures
- beam data library
- anatomical structures

## Most Popular systems:

**Pinnacle (Philips Medical systems)**

**ADAC -> Pinnacle3(Philips)**


**Monaco (CMS/Elekta)**

**Eclipse (Varian Medical Systems)**

**RapidArc: see([varian.com/us/oncology/treatments/treatment\\_techniques/rapidarc/resources.html](http://varian.com/us/oncology/treatments/treatment_techniques/rapidarc/resources.html))**

.....

## A RapidArc view





- Dose distribution
- Dose-Volume Histograms
- Biological indices

• Reconstructed radiographs (DRR)

• Field shape or Position of leaves

• Treatment parameters  
• Treatment time (monitor units)



# 7. QUANTIFICATION

(SPECT & PET)



## Definition of SUV (Standardized Uptake Value):



Coefficient used in Oncology for semiquantitative analysis

The percent injected dose per gram of tissue:

$$\text{SUV} = C_T \cdot W_s / d_T \cdot D_{inj}$$

Where:  $C_T$  (in mCi/cc) is obtained from counts/pixel/time from PET ROI.


$d_T = W_T / V_T$  (weight to volume of studied tissue) is the density in the region (often 1 g/cc)

$D_{inj}$  being the injected dose

$W_s$  is the total weight of the patient)

SUV=unitless parameter (from 1 to about 10)

Example of SUV



# 8. EXAMPLES OF USES @ HOSPITAL

# PET/CT (SPECT/CT) Scan protocol

Scout scan  
(5-20 sec)



CT PET

2. Selection  
of scan  
region (1-2  
min)




Scout scan image

3. Helical CT (1-2  
min)



CT PET

4. Whole-body PET  
(6-40 min)



CT PET

4000 PET/CT scanners operational worldwide


# SURVEY : Vaginal cancer

PET-CT is more powerful than PET alone....


**CT only**



**PET+CT**



**\* PET only**



Biograph Scan duration: 15 min

5 beds; 3 min/bed; 8s/3i/6F

10.6 mCi; 90 min post-injection


A 50 year-old female patient restaged for vulvar cancer with history of NHL (Non-Hodgkin lymphoma),. The PET/CT scan shows focal uptake in right aspect of the vulva (SUV: 10.3). Adjacent focal anorectal uptake (SUV: 5.5). CT is negative with no abnormality seen. Only combination of CT and PET can show that!

# 9. SPECIFIC DEVELOPEMENTS

(With come back to Ultrasound)

# IFMP Time-of-Flight (TOF)

Institute  
For Medical Physics  
Institut pour la  
Physique Médicale




**10ps TOF resolution**  
 $\Delta x = 1.5\text{mm}$   
 $\text{SNR}_{\text{TOF}}/\text{SNR}_{\text{CONV}} = 16!$

$$\text{SNR}_{\text{TOF}} = 1/\sqrt{1.6} \cdot \sqrt{(D/\Delta d)} \cdot \text{SNR}_{\text{conv}}$$


Ds (ps)	Dx (cm)	SNR gain
100	1.5	5.2
300	4.5	3.0
500	7.5	2.3
1200	18.0	1.5

**SNR (10 mCi; no TOF)**



**SNR (5 mCi; with TOF)**

✓ **Reduced radiation dose**




✓ **Improved signal-to-noise**

# Already many specific devices



## Organ-specific imaging devices: brain



1961, Headshrinker, BNL



2011, PETHAT, Hamamatsu



2013, BrainPET, Hamamatsu



2008, RATCAP, BNL






2012, HELMETPET, Majewski



2015, HELMET\_CHIN, T. Yamaga

Courtesy: S. Majewski, West Virginia University

## Clear PEM is PET for Mammography





# Why ClearPEM Specific device is needed



(PEM = Positron Emission Mammography)



## ClearPEM breast cancer images



Same lesion seen by two medical imaging systems



→ Organ specific imaging devices can demonstrate superior performance as compared to commercially available wholebody clinical scanners.

Not a priority investment area for large imaging companies they are a good target for our medical imaging community and open up commercial niches.

Studies show that **breast Multifocal tumors** have a **different biology**, with an **increased potential to metastize to the axillary lymph nodes**

# Hybrid Device PEM – US (with Elastography) (now in clinical tests in Marseille-Nord Hospital)



Has supported this  
development

About CERN   Students & Educators   Scientists   CERN people  
Accelerators   Experiments   Physics   Computing   Engineering   Updates   Opinion

## ClearPEM clarifies breast cancer diagnosis

**ClearPEM Sonic**  
**A PET - US Hybrid**  
**Device for**  
**Mammography**

A multimodal scanner  
to improve the  
diagnosis of breast  
diseases.






ClearPEM-Sonic installed at Hôpital Nord, in Marseilles. (Image: Benjamin Frisch/CERN)

# What is ClearPEM-Sonic

a multimodal scanner to improve the diagnosis of breast diseases.

- **Combines 3 info:**  
METABOLIC, MORPHOLOGIC and STRUCTURAL in multimodal PEM + US imaging technology
- The ultrasound scanner provides a map of tissues density variation in the region of interest
- New generation ultrasound scanner (Aixplorer) capable of quantitatively mapping the elastic properties of tissues (**ELASTOGRAPHY**)
- It complements the functional information provided by the ClearPEM with morphologic and structural information about lesions provided by US
- Metabolic information can be rapidly compared with morphological ones, all fused in single 3D-images easily accessible by hospital staff.





**Imaging tool for pancreas and prostate cancer  
biomarker development**



FP7 project, Grant Agreement n°256984

**4 Tools**

● **Endo = endoscope**

- 1 for pancreas
- 1 for prostate

*Spatial resolution  
Biopsy*

● **TOF = Time-of-Flight**

*Other organs  
background rejection*

● **PET**

- Endoscopic head close to organ
- External plate for coincident

*Anatomic +  
Molecular imaging*

● **US = Ultrasound**

# ***In some Kind of Conclusion: The Future Healthcare Mission***

- \* **Personalized Medicine** is an emerging approach for disease treatment and prevention that takes into account **individual variability in genes, environment, and lifestyle** for each person
- \* To get there, we need to incorporate **many different types of data**, from:
  1. Data about the patient collected by health care providers and patients themselves
  2. Metabolomics (the chemicals in the body at a certain point in time)
  3. Microbiome (the collection of microorganism in or on the body)

**IMAGING**

**THE RIGHT TREATMENT**

**TO THE RIGHT PERSON**

**AT THE RIGHT TIME**

This requires targeting the cellular activity with the **highest possible sensitivity and specificity**


This requires **efforts on imaging instrumentation** : **Sensitivity, Spatial & Temporal resolution**

Facing the challenge of  
personalized medicine...


## What is Theranostic?

- i.e. molecular diagnostic agent + targeted therapeutic.
- The basic architecture is:
  - a **targeting agent** which directs the theranostic to a molecular target on the surface of a cell or tumor
  - a chelate in the form of an **imaging agent** (which enables visualization of the target) or a **therapeutic drug** (for delivery of treatment to the target site)
  - a **linker** to connect the two entities *(from Ronald Van Heertum, BioClinica)*

**Exemple : Lutathera** ,  $[^{177}\text{Lutetium-DOTA0-Tyr3}]$ -Octreotate, for **patients with Endocrine Gastroenteropancreatic tumors** , is a radiolabeled somatostatin analog that selectively targets somatostatin receptors over-expressed in these tumors. (Lutathera is produced by our neighbour AAA ltd near CERN)




# 10. CONCLUSION




During last decade: **Impressive progress** in Medical Imaging

Due to **enormous** work on the technical front:

- New detectors
- Software
- Training
- Radiation Protection



About 4000 PET/CT scanners operational worldwide (start in 2000')



PET/MR scanners are beginning now



**All that is for the main benefit of patients....**



**Thanks a lot for  
the gentle attention!**